Sanofi-Aventis US faces class-action sex bias lawsuit

Sanofi-Aventis US faces class-action sex bias lawsuit

	Published : Fri, 31 Aug 2007 08:38 By : Agencies Print this Story

NEW YORK (Thomson Financial) - Sanofi-Aventis US, the American arm of the French pharmaceuticals group, is facing a class-action lawsuit for alleged sexual discrimination and harassment.

Three former employees of Sanofi-Aventis US have joined an initial lawsuit filed on March 14 by Karen Bellifemine, a sales representative at the Bridgewater, New Jersey-based group.

The plaintiffs accuse Sanofi-Aventis US management of sex discrimination, saying that they were not promoted because of their gender and were paid significantly less than their male colleagues. The women are seeking more than 300 mln usd in compensation.

Sanofi-Aventis denied the allegations.

The original plaintiff, Bellifemine, began working at Sanofi-Aventis US in 1995 and is still employed there. The other three -- Amy Zeoli, Michelle Popa and Sue Sullivan -- said they resigned in 2006-2007 over the situation.

All four plaintiffs said their bosses had sexually harassed them, in words or unwelcome gestures. Some said they suffered repeated incidences of harassment after reporting the offensive behaviour to management.

'We'll be moving for class certification on behalf of approximately 6,000 women in the next few months, after we obtain the statistical data which shows that Sanofi pays its female pharma reps less than men, and fails to promote women at the same rate as men,' said a lawyer for the plaintiffs, Steven Wittels of Sanford Wittels & Heisler LLP.

'We are confident that the data will support these claims,' he said.

Sanofi-Aventis US issued a terse statement denying the women's allegations. 'We are confident that the suit lacks merit and that all of our employees are treated fairly and in compliance with all applicable federal and state laws,' the company said.

tf.TFN-Europe_newsdesk@thomson.com

afp/cmr/cm2

The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.